期刊文献+

胸腰椎骨质疏松型骨折患者术后早期应用唑来膦酸的临床效果及对骨密度和骨代谢的影响 被引量:1

下载PDF
导出
摘要 目的:探讨胸腰椎骨质疏松型骨折患者术后早期应用唑来膦酸的临床效果及对骨密度和骨代谢的影响。方法:胸腰椎骨质疏松型骨折患者82例,随机分为对照组和观察组各41例。两组均接受经皮椎体成形术,对照组术后予以常规补充钙剂及维生素D3,观察组在对照组基础上术后早期静滴唑来膦酸。比较两组手术前后骨密度、骨代谢水平、疼痛及胸腰椎功能。结果:术前两组骨密度比较,差异无统计学意义(P=0.708);术后3个月两组胸腰椎骨密度均升高,观察组为0.99±0.13 g/cm^(2),高于对照组的0.80±0.10 g/cm^(2),差异有统计学意义(P<0.001)。两组术前Ⅰ型前胶原氨基端前肽(PINP)、Ⅰ型胶原羧基端肽特殊序列(β-CTX)、碱性磷酸酶(ALP)水平比较,差异均无统计学意义(P>0.05);与术前比较,两组术后PINP、ALP水平升高,β-CTX水平降低,差异均有统计学意义(P<0.05);观察组术后PINP为81.95±8.12μg/L,ALP为61.45±5.15 U/L,分别高于对照组的76.63±7.26μg/L和57.03±4.02 U/L,β-CTX为0.45±0.11μg/L,低于对照组的0.63±0.12μg/L,差异均有统计学意义(P<0.05)。两组术前疼痛VAS评分、ODI指数比较,差异均无统计学意义(P>0.05);与术前比较,两组术后VAS评分及ODI指数下降,差异均有统计学意义(P<0.05);观察组术后VAS评分为1.95±0.25分,ODI指数为(1.95±0.25)%,分别低于对照组的2.63±0.28分和(35.59±5.06)%,差异均有统计学意义(P<0.05)。结论:胸腰椎骨质疏松型骨折患者经皮椎体成形术后早期应用唑来膦酸通过调节骨代谢水平,提高骨密度,有助于进一步缓解疼痛,恢复胸腰椎功能。
出处 《交通医学》 2021年第4期353-354,357,共3页 Medical Journal of Communications
  • 相关文献

参考文献6

二级参考文献69

  • 1Wang G,Yang H,Chen K.Osteoporotic vertebral compression fractures with an intravertebral cleft treated by percutaneous balloon kyphoplasty.J Bone Joint Surg Br,2010,92(11):1553-1557.
  • 2Mao H,Zou J,Geng D,et al.Osteoporotic vertebral fractures without compression:key factors of diagnosis and initial outcome of treatment with cement augmentation.Neuroradiology,2012,54(10):1137-1143.
  • 3Parker M,Johansen A.Hip fracture.BMJ,2006,333(7557):27-30.
  • 4L?nnroos E,Kautiainen H,Karppi P,et al.Incidence of second hip fractures.A population-based study.Osteoporos Int,2007,18(9):1279-1285.
  • 5Black DM,Delmas PD,Eastell R,et al.Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.N Engl J Med,2007,356(18):1809-1822.
  • 6Black DM,Reid IR,Boonen S,et al.The effect of 3 versus6 years of zoledronic acid treatment of osteoporosis:a randomized extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2012,27(2):243-254.
  • 7Black DM,Reid IR,Cauley JA,et al.The effect of 6 versus9 years of zoledronic acid treatment in osteoporosis:a randomized second extension to the HORIZON-Pivotal Fracture Trial(PFT).J Bone Miner Res,2015,30(5):934-944.
  • 8Lyles KW,Colón-Emeric CS,Magaziner JS,et al.Zoledronic acid and clinical fractures and mortality after hip fracture.N Engl J Med,2007,357(18):1799-1809.
  • 9Black DM,Schwartz AV,Ensrud KE,et al.Effects of continuing or stopping alendronate after 5 years of treatment:the Fracture Intervention Trial Long-term Extension(FLEX):a randomized trial.JAMA,2006,296(24):2927-2938.
  • 10Bone HG,Hosking D,Devogelaer JP,et al.Ten years'experience with alendronate for osteoporosis in postmenopausal women.N Engl J Med,2004,350(12):1189-1199.

共引文献1111

同被引文献20

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部